MedImmune, LLC

États‑Unis d’Amérique


Commandez votre montre hebdomadaire MedImmune, LLC
Quantité totale PI 500
Quantité totale incluant filiales 519 (+ 19 pour les filiales)
Rang # Quantité totale PI 2 659
Note d'activité PI 3,1/5.0    184
Rang # Activité PI 3 633
Parent AstraZeneca PLC
Classe Nice dominante Produits pharmaceutiques, vétéri...

Brevets

Marques

177 4
44 3
268 0
4
 
Dernier brevet 2025 - Anti-o2 antibodies and uses thereof
Premier brevet 1993 - Suppression of hiv expression by...
Dernière marque 2021 - M
Première marque 1997 - SYNAGIS

Filiales

4 subsidiaries with IP (19 patents, 0 trademarks)

1 subsidiaries without IP

 S'inscrire grtuitement pour accéder à la liste des filiales

Industrie (Classification de Nice)

Derniers inventions, produits et services

2025 Invention Method of treating influenza a. Provided herein are methods for treating, reducing or preventing...
Invention Neutralizing anti-influenza b antibodies and uses thereof. The invention relates to antibodies a...
Invention Anti-o2 antibodies and uses thereof. The present disclosure provides binding proteins (e.g., ant...
Invention Methods of treating coronary artery disease. This invention relates to methods of lowering plasm...
Invention Decreasing staphylococcus aureus infections in colonized patients. The present disclosure is dir...
Invention Method and molecules. The present invention provides a bioconjugation method and compounds for u...
Invention Treatment of chronic obstructive pulmonary disease with anti-tslp antibody. The present disclosur...
2024 Invention Treatment of asthma with anti-tsl p antibody. The present disclosure, relates, in general, to me...
Invention Bispecific binding proteins and uses thereof. The disclosure generally provides proteins that bi...
Invention Anti-o1 antibodies and uses thereof. The present disclosure provides binding proteins (e.g., ant...
Invention Pd-1/tim-3 binding proteins for treatment of nsclc and chl. The disclosure relates to methods of...
Invention Pd-1/tim-3 binding proteins for treatment of nsclc and chl. The disclosure relates to methods of ...
Invention Treatment of corticosteroid dependent asthma with anti-tslp antibody. The present disclosure rela...
Invention Treatment of eosinophilic esophagitis with anti-tslp antibody. The present disclosure, relates, i...
Invention Pd-1/tigit binding proteins for cancer treatment. The disclosure relates to methods of treating ...
Invention Pd-1/tigit binding proteins for cancer treatment. The disclosure relates to methods of treating c...
Invention Steap2 directed t-cell engagers and compositions thereof. Provided are T ell engaging molecules ...
Invention Steap2 antibody drug conjugates and uses thereof. The present disclosure relates to binding mole...
Invention Steap2 directed t-cell engagers and compositions thereof. Provided are T cell engaging molecules ...
Invention Steap2 antibody drug conjugates and uses thereof. The present disclosure relates to binding molec...
Invention Optimized cd3 antigen binding domains. The present disclosure relates to antibodies or fragments...
Invention Optimized cd3 antigen binding domains. The present disclosure relates to antibodies or fragments ...
Invention Trispecific engineered antibodies. Provided herein are trispecific antibodies containing three a...
Invention Bispecific engineered antibodies. Provided herein is a multispecific antibody containing two ant...
Invention Bispecific engineered antibodies. Provided herein is a multispecific antibody containing two anti...
Invention Trispecific engineered antibodies. Provided herein are trispecific antibodies containing three an...
Invention Engineered antibodies. Provided herein are multispecific antibodies containing a lambda charge p...
Invention Engineered antibodies. Provided herein are multispecific antibodies containing a lambda charge pa...
Invention Fluidic mixer unit device for nanoparticle production. A device 100 for producing nanoparticles i...
Invention Antibody directed against s. aureus clumping factor a (clfa). The present disclosure is directed...
Invention Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concen...
Invention Bispecific pd-1 and tigit binding proteins and uses thereof. The disclosure relates to binding p...
Invention Treatment of chronic rhinosinusitis with anti-tslp antibody. The present disclosure, relates, in ...
Invention Neutralizing anti-influenza a antibodies and uses thereof. The invention relates to antibodies a...
Invention Compositions and methods of treating cancer with chimeric antigen receptors. This disclosure rel...
Invention Bcma monoclonal antibody-drug conjugate. The disclosure is directed to an antibody-drug conjugat...
2023 Invention Adeno-associated virus production platform. Provided herein is a novel rAAV-based HSV production ...
Invention Immune repertoire mining. The present invention provides a method for producing encapsulated nat...
Invention Compositions and methods of treating cancer with chimeric antigen receptors targeting claudin 18....
Invention Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic pro...
Invention Methods for expanding t cell populations. Provided herein are methods for manufacturing, expandi...
2022 Invention Clonal chinese hamster ovary cells and their use. Provided herein are clonal Chinese Hamster Ova...
Invention Anti-il-13 antibody formulation. The present invention relates to a pharmaceutical composition c...
Invention Modified fcrn binding fragments with improved half-life. The present disclosure relates to modif...
2021 P/S Pharmaceutical preparations and substances for treatment of respiratory diseases and disorders
Invention Bispecific binding proteins and uses thereof. The disclosure generally provides proteins that bin...
Invention Detergent and method for purifying a biotherapeutic. Provided herein is an environmentally compa...
Invention Stabilized igg4 antibodies and uses thereof. The disclosure relates to an antibody of the class ...
2019 Invention Branched moiety for use in conjugates. A tri-functional linker moiety: formula (I), where X and ...
2012 P/S Vaccines
2009 P/S Influenza vaccines for humans.
P/S Vaccines against flu.
2005 P/S Vaccines for use by humans in the prevention and treatment of viral infections.
2004 P/S Pharmaceutical preparations and substances for health care and medical clinical use. Health care ...
2003 P/S VACCINES
1998 P/S Pharmaceutical, veterinary and sanitary preparations and substances; vitamin preparations and vac...
P/S Humanized monoclonal antibody against respiratory syncytial virus.
1997 P/S A humanized monoclonal antibody against respiratory syncytial virus.